12 Health Care Stocks Moving In Tuesday's After-Market Session

Benzinga · 1d ago
Gainers
- Citius Pharmaceuticals (NASDAQ:CTXR) shares increased by 13.6% to $1.46 during Tuesday's after-market session. The company's market cap stands at $11.1 million.
- Cibus (NASDAQ:CBUS) stock rose 11.54% to $1.74. The company's market cap stands at $73.0 million.
- LakeShore Biopharma (NASDAQ:LSB) shares rose 9.11% to $1.04. The company's market cap stands at $18.5 million.
- NeuroOne Medical Tech (NASDAQ:NMTC) shares rose 6.62% to $0.74. The company's market cap stands at $32.9 million.
- Ontrak (NASDAQ:OTRK) shares rose 6.62% to $1.12. The market value of their outstanding shares is at $5.6 million.
- Nektar Therapeutics (NASDAQ:NKTR) stock increased by 6.29% to $26.0. The company's market cap stands at $118.3 million.
Losers
- XTL Biopharmaceuticals (NASDAQ:XTLB) shares declined by 11.5% to $1.16 during Tuesday's after-market session. The market value of their outstanding shares is at $8.9 million.
- OneMedNet (NASDAQ:ONMD) shares fell 10.35% to $0.61. The company's market cap stands at $10.3 million.
- Forte Biosciences (NASDAQ:FBRX) shares declined by 10.31% to $12.71. The market value of their outstanding shares is at $84.0 million.
- InspireMD (NASDAQ:NSPR) stock declined by 8.55% to $2.25. The market value of their outstanding shares is at $77.2 million.
- CASI Pharmaceuticals (NASDAQ:CASI) shares declined by 8.09% to $1.25. The market value of their outstanding shares is at $19.0 million.
- Lixte Biotechnology (NASDAQ:LIXT) shares decreased by 7.95% to $0.8. The market value of their outstanding shares is at $2.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.